FRESENIUS MEDICAL CARE AG Expense Relating To Leases Of Lowvalue Assets For Which Recognition Exemption Has Been Used
FRESENIUS MEDICAL CARE AG (FMS) reported Expense Relating To Leases Of Lowvalue Assets For Which Recognition Exemption Has Been Used of EUR 14.25 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed · last filed 2026-02-24
- FRESENIUS MEDICAL CARE AG expense relating to leases of lowvalue assets for which recognition exemption has been used for the quarter ending 2019-12-31 was 4.38M EUR.
- FRESENIUS MEDICAL CARE AG expense relating to leases of lowvalue assets for which recognition exemption has been used for the quarter ending 2019-09-30 was 9.05M EUR.
- FRESENIUS MEDICAL CARE AG expense relating to leases of lowvalue assets for which recognition exemption has been used for the quarter ending 2019-06-30 was 5.67M EUR.
- FRESENIUS MEDICAL CARE AG expense relating to leases of lowvalue assets for which recognition exemption has been used for the quarter ending 2019-03-31 was 6.14M EUR.
| Period end | Expense Relating To Leases Of Lowvalue Assets For Which Recognition Exemption Has Been Used 3 month | Expense Relating To Leases Of Lowvalue Assets For Which Recognition Exemption Has Been Used 6 month | Expense Relating To Leases Of Lowvalue Assets For Which Recognition Exemption Has Been Used 9 month | Expense Relating To Leases Of Lowvalue Assets For Which Recognition Exemption Has Been Used 12 month |
|---|---|---|---|---|
| 2025-12-31 | 14.25M EUR 20-F · filed 2026-02-24 | |||
| 2024-12-31 | 20.10M EUR 20-F · filed 2026-02-24 | |||
| 2023-12-31 | 22.19M EUR 20-F · filed 2026-02-24 | |||
| 2022-12-31 | 17.42M EUR 20-F · filed 2025-02-25 | |||
| 2021-12-31 | 23.18M EUR 20-F · filed 2024-02-20 | |||
| 2020-12-31 | 27.36M EUR 20-F · filed 2023-02-22 | |||
| 2019-12-31 | 4.38M EUR derived: 20-F 12 month − 6-K 9 month · filed 2022-02-22 | 13.43M EUR derived: sum of 2 quarters · filed 2022-02-22 | 19.10M EUR derived: sum of 3 quarters · filed 2022-02-22 | 25.24M EUR 20-F · filed 2022-02-22 |
| 2019-09-30 | 9.05M EUR 6-K · filed 2019-10-31 | 14.72M EUR derived: sum of 2 quarters · filed 2019-10-31 | 20.86M EUR 6-K · filed 2019-10-31 | |
| 2019-06-30 | 5.67M EUR 6-K · filed 2019-07-30 | 11.81M EUR 6-K · filed 2019-07-30 | ||
| 2019-03-31 | 6.14M EUR 6-K · filed 2019-05-02 |